In 2014, the College of American Pathologists developed an evidence-based guideline to address analytic validation of immunohistochemical assays. Fourteen recommendations were offered. Per the National Academy of Medicine standards for developing trustworthy guidelines, guidelines should be updated when new evidence suggests modifications.


To assess evidence published since the release of the original guideline and develop updated evidence-based recommendations.


The College of American Pathologists convened an expert panel to perform a systematic review of the literature and update the original guideline recommendations using the Grading of Recommendations Assessment, Development and Evaluation approach.


Two strong recommendations, 1 conditional recommendation, and 12 good practice statements are offered in this updated guideline. They address analytic validation or verification of predictive and nonpredictive assays, and recommended revalidation procedures following changes in assay conditions.


While many of the original guideline statements remain similar, new recommendations address analytic validation of assays with distinct scoring systems, such as programmed death receptor-1 and analytic verification of US Food and Drug Administration approved/cleared assays; more specific guidance is offered for validating immunohistochemistry performed on cytology specimens.

This content is only available as a PDF.

Author notes

Supplemental digital content is available for this article. See text for hyperlink.

Dr Goldsmith is the Guideline Expert Panel Chair.

Competing Interests

Authors’ disclosures of potential conflicts of interest and author contributions are found in the Appendix at the end of this article.

Supplementary data